United States - English - NLM (National Library of Medicine)

mwi - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - ndc 13985-354-04  vetone atropine sulfate injection 1/120 grain sterile multiple dose vial keep out of reach of children. for veterinary use only. caution:   federal law restricts this drug to use by or on the order of a licensed veterinarian.  v1 510221                           net contents: 100 ml for intravenous, intramuscular, or subcutaneous use composition : each ml contains : atropine sulfate  ............................  0.54 mg sodium chloride .................................  9 mg benzyl alcohol (preservative)...............  1.5% water for injection  ...............................  q.s. ph adjusted with sulfuric acid when necessary.

United States - English - NLM (National Library of Medicine)

henry schein animal health - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - henry schein animal health atroject  satm injection 1/120 grain sterile multiple dose vial for animal use only caution: federal law restricts this drug to use by or on the order of a licensed veterinarian. net contents: 100 ml distibuted exclusively by henry schein animal health dublin, oh 43017 www.henryscheinvet.com for intravenous, intramuscular, or subcutaneous use composition : each ml contains : atropine sulfate  ............................  0.54 mg sodium chloride .................................  9 mg benzyl alcohol (preservative)...............  1.5% water for injection  ...............................  q.s. ph adjusted with sulfuric acid when necessary.

United States - English - NLM (National Library of Medicine)

covetrus north america - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - covetrus atropine sulfate injection injection 1/120 grain sterile, multiple-dose vial for animal use only. caution: federal law restricts this drug to use by or on the order of a licensed veterinarian. net contents: 100 ml for interveneous, intramuscular, or subcutaneous use composition : each ml contains: atropine sulfate  ............................  0.54 mg sodium chloride .................................  9 mg benzyl alcohol (preservative)...............  1.5% water for injection  ...............................  q.s. ph adjusted with sulfuric acid when necessary.

United States - English - NLM (National Library of Medicine)

prasco laboratories - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i), scopolamine hydrobromide (unii: 451ifr0gxb) (scopolamine - unii:dl48g20x8x) - - glaucoma; - obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); - obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.); - paralytic ileus, intestinal atony of the elderly or debilitated patient; - unstable cardiovascular status in acute hemorrhage; - severe ulcerative colitis especially if complicated by toxic megacolon; - myasthenia gravis; - hiatal hernia associated with reflux esophagitis; - in patients with known hypersensitivity to any of the ingredients. phenobarbital is contraindicated in acute intermittent porphyria and in those patients in whom phenobarbital produces restlessness and/or excitement. phenobarbital may be habit forming and should not be administered to individuals known to be addiction prone or to those with a history of physical and/or psychological dependence upon drugs (see warnings ). in patients habituated to barbiturates, abrupt withdrawal may produce delirium or convulsions.

United States - English - NLM (National Library of Medicine)

prasco laboratories - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i), scopolamine hydrobromide (unii: 451ifr0gxb) (scopolamine - unii:dl48g20x8x) - • glaucoma; • obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); • obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.); • paralytic ileus, intestinal atony of the elderly or debilitated patient; • unstable cardiovascular status in acute hemorrhage; • severe ulcerative colitis especially if complicated by toxic megacolon; • myasthenia gravis; • hiatal hernia associated with reflux esophagitis; • in patients with known hypersensitivity to any of the ingredients. phenobarbital is contraindicated in acute intermittent porphyria and in those patients in whom phenobarbital produces restlessness and/or excitement. phenobarbital may be habit forming and should not be administered to individuals known to be addiction prone or to those with a history of physical and/or psychological dependence upon drugs (see warnings ). in patients habituated to barbiturates, abrupt withdrawal may produce delirium or convulsion

United States - English - NLM (National Library of Medicine)

ingenus pharmaceuticals, llc - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i), scopolamine hydrobromide (unii: 451ifr0gxb) (scopolamine - unii:dl48g20x8x) - - glaucoma; - obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); - obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.); - paralytic ileus, intestinal atony of the elderly or debilitated patient; - unstable cardiovascular status in acute hemorrhage; - severe ulcerative colitis especially if complicated by toxic megacolon; - myasthenia gravis; - hiatal hernia associated with reflux esophagitis; - in patients with known hypersensitivity to any of the ingredients. phenobarbital is contraindicated in acute intermittent porphyria and in those patients in whom phenobarbital produces restlessness and/or excitement. phenobarbital may be habit forming and should not be administered to individuals known to be addiction prone or to those with a history of physical and/or psychological dependence upon drugs (see warnings). in patients habituated to barbiturates, abrupt withdrawal may produce delirium or convulsions.

United States - English - NLM (National Library of Medicine)

ingenus pharmaceuticals, llc - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i), scopolamine hydrobromide (unii: 451ifr0gxb) (scopolamine - unii:dl48g20x8x) - - glaucoma;  - obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy);  - obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.);  - paralytic ileus, intestinal atony of the elderly or debilitated patient; - unstable cardiovascular status in acute hemorrhage;  - severe ulcerative colitis especially if complicated by toxic megacolon;  - myasthenia gravis;  - hiatal hernia associated with reflux esophagitis;  - in patients with known hypersensitivity to any of the ingredients. phenobarbital is contraindicated in acute intermittent porphyria and in those patients in whom phenobarbital produces restlessness and/or excitement. phenobarbital may be habit forming and should not be administered to individuals known to be addiction prone or to those with a history of physical and/or psychological dependence upon drugs (see warnings ). in patients habituated to barbiturates, abrupt withdrawal may produce delirium or convulsions.

United States - English - NLM (National Library of Medicine)

apotex corp. - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - atropine sulfate ophthalmic solution, 1% is indicated for: atropine sulfate ophthalmic solution should not be used in anyone who has demonstrated a previous hypersensitivity or known allergic reaction to any ingredient of the formulation because it may recur. pregnancy category c: there are no adequate and well-controlled studies of atropine sulfate in pregnant women. animal development and reproduction studies have not been conducted with atropine sulfate. since it is not known whether topically administered atropine sulfate can cause fetal harm, atropine sulfate ophthalmic solution, 1% should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. traces of atropine have been found in human milk following administration of atropine solution for injection. because some systemic absorption occurs from topical administration, caution should be exercised when atropine sulfate ophthalmic solution, 1% is administered to a nursing woman. due to the potential for systemic absorption of atropine sulfate ophthalmic solution, the use of atropine sulfate ophthalmic solution, 1% in children under the age of 3 months is not recommended and the use in children under 3 years of age should be limited to no more than one drop per eye per day. no overall differences in safety and effectiveness have been observed between elderly and younger adult patients.

United States - English - NLM (National Library of Medicine)

akorn - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - atropine sulfate ophthalmic solution, usp 1% is indicated for: atropine sulfate ophthalmic solution should not be used in anyone who has demonstrated a previous hypersensitivity or known allergic reaction to any ingredient of the formulation because it may recur. pregnancy category c: there are no adequate and well-controlled studies of atropine sulfate in pregnant women. animal development and reproduction studies have not been conducted with atropine sulfate. since it is not known whether topically administered atropine sulfate can cause fetal harm, atropine sulfate ophthalmic solution, usp 1% should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. traces of atropine have been found in human milk following administration of atropine solution for injection. because some systemic absorption occurs from topical administration, caution should be exercised when atropine sulfate ophthalmic solution, usp 1% is administered to a nursing woman. due to the potential fo

United States - English - NLM (National Library of Medicine)

med-pharmex, inc - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - ndc 54925-063-10 atropine sulfate sterile multiple dose vial injection 1/120 grain net contents: 100 ml keep out of reach of children for animal use only caution:   federal law restricts this drug to use by or on the order of a licensed veterinarian. med -pharmex incorporated pomona, ca 91767 for intravenous, intramuscular, or subcutaneous use composition : each ml contains: atropine sulfate  ............................  0.54 mg sodium chloride .................................  9 mg benzyl alcohol (preservative)...............  1.5% water for injection  ...............................  q.s. ph adjusted with sulfuric acid when necessary.